PATENT CLAIM ANALYSIS

Application Number: 16414350
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["424", "499000"]

Abstract:
Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Claim (Index 17):
The method of  claim 12 , wherein said pharmaceutically acceptable excipient comprises microcrystalline cellulose.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 100.0
- Lexical Diversity: 1.69565
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12069667', '12839190', '15471334', '12548292', '14921860']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7965213124487194
- 35 USC 102 Novelty (BERT): 0.5257533686592887
- Combined Prediction Score: 0.7694445180697763
- Mean Citation Score: 300.153426
- Max Citation Score: 311.41263
- Similarity Product: 156.04946402370038

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test